In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.

Merger with Ranbaxy might get delayed: Sun CFO Baldota

The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.

Margins may cool, but revenue growth seen solid: Sun Pharma

Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma cautioned that the jump in operating margin to 44 percent seen during the quarter may not be sustained.

Sun Pharma: Can the stock climb higher than all-time high?

Sun Pharma was at lifetime high yesterday at Rs 854. It has received final approval for Novartis's Reclast/Aclasta, which is used in the treatment of osteoporosis.

Margins may be hit on one-off items in EBITDA: Sun Pharma

Uday Baldota, VP- investor relations, Sun Pharma tells CNBC-TV18 that apart from the drug Taro‘s stellar contribution, other business segments also performed well

Wyeth's claim on Protonix unjustified: Sun Pharma

“We strongly believe that we have reasons to disagree with the claim that they have made. Fundamentally, we also believe that the patent invalidated is something that we will continue to fight for, Uday Baldota, vice president - investor relations, Sun Pharma told CNBC-TV18.

Limited competition, Forex gains pump Taro nos: Sun Pharma

In an interview to CNBC-TV18, Uday Baldota of Sun Pharma says the results of Taro, have been boosted by lack of competition and Forex gains. With 'very strong numbers' reported by Taro this quarter, Badola says its delisting process is still ongoing.

Sun Pharma eyes revenue growth of 28-30% in FY12

Sun Pharmaceutical is eyeing revenue growth of 28-30% in FY12, said Uday Baldota of Sun Pharma. In an interview to CNBC-TV18, Baldota said that Taro Pharmaceutical Industries reported strong margins this quarter.

With Sun Pharma-Merck striking JV, why is SPARC shining?

According to CNBC-TV18's research analyst Ekta Batra it's SPARC which has emerged as the winner from this deal between Sun Pharma and Merck. They are targeting a portfolio of around 12 drugs in around 100 countries but the focus is expected to be the top 10 countries which are expected to contribute around 80% of revenues.

What is Lupin's acquisition agenda for the future?

Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.